drugset / Trial / NCT01087723

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

NCT01087723

Phase 3 Completed 2198 enrolled The Medicines Company
RandomizedParallel-groupOpen-labelTreatment

Summary

To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary percutaneous coronary intervention (PCI) management strategy, presenting either via ambulance or to centers where PCI is not performed.

Timeline

Start
2010-03
Primary completion
2013-08
Completion
2014-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 0.25 mg/kg Intravenous
Comparator Heparin Other / unclassified 60 iu/kg
Comparator Heparin Other / unclassified 100 iu/kg